TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of acinetobacter baumannii

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 12, 2013, Pages 2786-2791

  Krizova, Lenka ^a,b,c   Poirel, Laurent ^c   Nordmann, Patrice ^c   Nemec, Alexandr ^a  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Associated French National Reference Center for Antibiotic Resistance: Carbapenemase producing Enterobacteriaceae   (France)

Author keywords

Gene expression; Mechanisms of resistance; Multidrug resistance; Transformation

Indexed keywords

AZTREONAM; BETA LACTAMASE TEM 1; BETA LACTAMASE TEM 19; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; PIPERACILLIN; SULBACTAM; TAZOBACTAM; TICARCILLIN; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; AMPLICON; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; COPY NUMBER VARIATION; ELECTROPORATION; GENE EXPRESSION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION;

GENE EXPRESSION; MECHANISMS OF RESISTANCE; MULTIDRUG RESISTANCE; TRANSFORMATION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; BETA-LACTAMASES; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; GENE DOSAGE; GENE EXPRESSION PROFILING; HUMANS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SULBACTAM;

EID: 84887666298     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt275     Document Type: Article

References (33)

1. PelegAY, Seifert H,Paterson DL. Acinetobacter baumannii:emergenceofa successful pathogen. Clin Microbiol Rev 2008; 21: 538-582.
2. Zarrilli R, Di Popolo A, Bagattini M et al. Clonal spread and patient risk factors for acquisition of extensively drug-resistant Acinetobacter baumannii in a neonatal intensive care unit in Italy. J Hosp Infect 2012; 82: 260-5.
3. Vila J, Pachón J. Therapeutic options for Acinetobacter baumannii infections: an update. Expert Opin Pharmacother 2012; 13: 2319-2336.
4. Higgins PG, Wisplinghoff H, Stefanik D et al. In vitro activities of the b-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with b-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 2004; 48: 1586-1592.
5. Urban C, Go E, Mariano N et al. Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptible Acinetobacter baumannii. FEMS Microbiol Lett 1995; 125: 193-197.
6. Santimaleeworagun W, Wongpoowarak P, Chayakul P et al. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health 2011; 42: 890-900.
7. Tripodi MF, Durante-mangoni E, Fortunato R et al. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 2007; 30: 537-540.
8. Peck KR, Kim MJ, Choi JY et al. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates. J Med Microbiol 2012; 61: 353-60.
9. Joly-guillou ML, Vallée E, Bergogne-bérézin E et al. Distribution of b-lactamases and phenotype analysis in clinical strains of Acinetobacter calcoaceticus. J Antimicrob Chemother 1988; 22: 597-604.
10. Joly-guillou ML, Decré D, Herrman JL et al. Bactericidal in-vitro activity of b-lactams and b-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. J Antimicrob Chemother 1995; 36: 619-629.
11. Ben RJ, Yang MC, Hsueh JC et al. Molecular characterisation of multiple drug-resistant Acinetobacter baumannii isolates in southern Taiwan. Int J Antimicrob Agents 2011; 38: 403-408.
12. Nemec A, Krizová L, Maixnerová M et al. Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II. J Antimicrob Chemother 2008; 62: 484-489.
13. Diancourt L, Passet V, Nemec A et al. The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS One 2010; 5: e10034.
14. NemecA, Dijkshoorn L, van der Reijden TJK. Long-termpredominanceof two pan-European clones among multi-resistant Acinetobacter baumannii strains in the Czech Republic. J Med Microbiol 2004; 53: 147-153.
15. Krizova L, Nemec A. A 63 kb genomic resistance island found in a multidrug-resistant Acinetobacter baumannii isolate of European clone I from 1977. J Antimicrob Chemother 2010; 65: 1915-1918.
16. Krizova L, Dijkshoorn L, Nemec A. Diversity and evolution of AbaR genomic resistance islands in Acinetobacter baumannii strains of European clone I. Antimicrob Agents Chemother 2011; 55: 3201-6.
17. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement M100-S17. CLSI,Wayne, PA, USA, 2011.
18. Waltner-toews RI, Paterson DL, Qureshi ZA et al. Clinical characteristics of bloodstream infections due to ampicillin-sulbactam-resistant, non-extended- spectrum-b-lactamase-producing Escherichia coli and the role of TEM-1 hyperproduction. Antimicrob Agents Chemother 2011; 55: 495-501.
19. Hornsey M, Ellington MJ, DoumithM et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 1589-1593.
20. Lee C, Kim J, Shin SG et al. Absolute and relative QPCR quantification of plasmid copy number in Escherichia coli. J Biotechnol 2006; 123: 273-280.
21. Higgins PG, Wisplinghoff H, Stefanik D et al. Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J Antimicrob Chemother 2004; 54: 821-823.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 22DDCT method. Methods 2001; 25: 402-408.
23. Héritier C, Poirel L, Lambert T et al. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49: 3198-3202.
24. Nemec A, Janda L, MelterOet al. Genotypic and phenotypic similarity of multiresistant Acinetobacter baumannii isolates in the Czech Republic. J Med Microbiol 1999; 48: 287-296.
25. Adams MD, Goglin K, Molyneaux N et al. Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. J Bacteriol 2008; 190: 8053-8064.
26. Lartique MF, Leflon-guibout V, Poirel L et al. Promoters P3, Pa/Pb, P4, and P5 upstream from blaTEM genes and their relationship to b-lactam resistance. Antimicrob Agents Chemother 2002; 46: 4035-4037.
27. Pérez-moreno MO, Pérez-moreno M, Carulla M et al. Mechanisms of reduced susceptibility to amoxycillin-clavulanic acid in Escherichia coli strains from the health region of Tortosa (Catalonia, Spain). Clin Microbiol Infect 2004; 10: 234-241.
28. Wu PJ, Shannon K, Phillips I. Mechanisms of hyperproduction of TEM-1 b-lactamase by clinical isolates of Escherichia coli. J Antimicrob Chemother 1995; 36: 927-939.
29. Mabilat C, Courvalin P. Development of 'oligotyping' for characterization and molecular epidemiology of TEM b-lactamases in members of the family Enterobacteriaceae. Antimicrob Agents Chemother 1990; 34: 2210-2216.
30. Matagne A, Lamotte-brasseur J, Fre're JM. Catalytic properties of class A b-lactamases: efficiency and diversity. Biochem J 1998; 330: 581-598.
31. Giakkoupi P, Tzelepi E, Tassios PT et al. Detrimental effect of the combination of R164S with G238S in TEM-1 b-lactamase on the extended-spectrum activity conferred by each single mutation. J Antimicrob Chemother 2000; 45: 101-104.
32. Brenner DG, Knowles JR. Penicillanic acid sulfone: an unexpected isotope effect in the interaction of 6 a- and 6 b-monodeuterio and of 6,6-dideuterio derivatives with RTEM b-lactamase from Escherichia coli. Biochemistry 1981; 20: 3680-3687.
33. Drawz SM, Bonomo RA. Three decades of b-lactamase inhibitors. Clin Microbiol Rev 2010; 23: 160-201.